Post-Cardiac Injury Syndrome After Infarction: NSAID, Colchicine, or Aspirin Alone
New pericardial inflammation twelve days after a large anterior infarction needs treating, but the usual first-line drug for pericarditis carries a specific, separate concern in a patient this soon after his heart attack.
F.M., a 63-year-old man, became a grandfather for the first time three weeks ago and has spent every day since counting down to being cleared to hold the baby without his cardiac monitor stickers peeling off in the process. His anterior STEMI, twelve days ago, was treated quickly — a drug-eluting stent to a fully occluded left anterior descending artery — and his recovery had been, until two days ago, exactly what everyone hoped for: walking the hallway, appetite back, talking more about his granddaughter than his ejection fraction.
The new chest pain is different from what brought him in the first time. It's sharp rather than crushing, worse lying flat and better leaning forward, and it came with a low-grade fever his nurse caught on a routine check. On exam, a friction rub is audible over his chest — the sound of an inflamed pericardium rubbing against itself with each heartbeat — and his echocardiogram, ordered the same day, shows a small pericardial effusion that wasn't there at discharge planning three days earlier. His inflammatory markers, already elevated from the infarction itself, have climbed further. Post-cardiac injury syndrome, an inflammatory pericardial reaction to myocardial injury that can appear anywhere from days to weeks after a heart attack, fits every part of this picture.
Treating it should be straightforward, except that he is twelve days out from a large anterior infarction, already on dual antiplatelet therapy, and the anti-inflammatory drugs used for ordinary pericarditis — non-aspirin NSAIDs particularly — carry a specific, separate concern in this setting that has nothing to do with his stomach or his kidneys: older but still-cited data linking non-aspirin NSAIDs given in the early weeks after a myocardial infarction to impaired infarct scar formation and worse remodeling. The obvious workaround — escalate the aspirin he is already taking to an anti-inflammatory dose — runs into a second constraint that has nothing to do with the pericardium at all: his P2Y12 inhibitor is ticagrelor, which carries a boxed warning that maintenance aspirin above 100 milligrams a day reduces its effectiveness. The condition and the standard treatments for it are not obviously compatible with the week he's twelve days out from.
At the bedside, twelve days post-infarction
I'd treat this with high-dose aspirin as the primary anti-inflammatory agent — 650 to 1000 milligrams three times daily — since he's already on aspirin for his dual antiplatelet regimen, and escalating to an anti-inflammatory dose treats the pericardial inflammation directly while avoiding the non-aspirin-NSAID infarct-healing concern entirely. I'd add colchicine as an adjunct; it has a well-established, favorable safety profile in the post-MI setting and reduces the chance of this recurring.
High-dose aspirin on top of his existing dual antiplatelet therapy, plus colchicine, is a real amount of new gastrointestinal burden to add at once in a diabetic patient. His effusion is small, there's no tamponade physiology, and this may well be self-limited. I'd rather start with standard-dose aspirin — which he's already taking — plus colchicine, and reserve dose escalation for if he doesn't improve, rather than compounding his bleeding risk unnecessarily by treating this at maximum intensity from day one.
Worth being precise about which drug the post-MI concern actually applies to. The infarct-healing signal is specific to non-aspirin NSAIDs — ibuprofen, indomethacin, and similar agents — not to aspirin itself. But that doesn't make the aspirin route free, and this is the part I'd want said out loud before anyone writes for 650 milligrams three times a day: he is on ticagrelor. Ticagrelor carries a boxed warning that maintenance aspirin above 100 milligrams daily reduces its effectiveness — the North American signal out of PLATO — and anti-inflammatory aspirin dosing is an order of magnitude past that line, in a man twelve days out from a drug-eluting stent in a fully occluded left anterior descending. Blunting his P2Y12 inhibition to treat a small effusion is the wrong trade. Colchicine is the right anchor here: its evidence in pericarditis and post-pericardiotomy syndromes is solid, though I'd be careful not to borrow the separate post-infarction cardiovascular-prevention claim, where the largest trial came out flatly neutral. So: colchicine added, aspirin left at its current antiplatelet dose, and if this doesn't settle, the escalation conversation is about a short corticosteroid course or switching him to clopidogrel first — not about quietly pushing his aspirin up underneath the ticagrelor.
Agreed: standard-dose aspirin continued rather than switched or escalated — escalation being constrained by ticagrelor, not merely deferred — colchicine added, ibuprofen and steroids avoided, close monitoring of his effusion size and symptoms over the following days.
Not agreed, and the reason the plan carries a defined branch point rather than a single expectation:
Continue the current regimen and taper colchicine over the following weeks per standard course.
Escalate without raising his aspirin above 100 mg daily while he remains on ticagrelor — a short corticosteroid course, or a switch to clopidogrel first if anti-inflammatory aspirin dosing is genuinely wanted — and still without introducing a non-aspirin NSAID.